Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AK146D1 alone or combined with AK112 in advanced urothelial carcinoma
CTR20262204Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of AK146D1 and ivonescimab in transitional cell carcinoma (TCC) (2 arms), sponsored by Akeso, Inc. Primary endpoints: Safety and tolerability and Objective response rate. Started Aug 2026; status: active.
02
Drugs
AK146D1ivonescimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20262204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262204.